Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial

被引：0
作者：
Lu, S. [1 ]
Cheng, Y. [2 ]
Huang, D. [3 ]
Sun, Y. [4 ]
Wu, L. [5 ]
Zhou, C. [6 ]
Zhou, J. [7 ]
Guo, Y. [8 ]
Chen, L. [9 ]
Shao, J. [9 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Caner Ctr, Shanghai, Peoples R China
[2] Jilin Canc Hosp, Dept Thorac Oncol, Changchun, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Thorac Oncol, Tianjin, Peoples R China
[4] Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Peoples R China
[5] Hunan Canc Hosp, Dept Thorac Med 2, Changsha, Peoples R China
[6] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis,Resp Med Dept, ffiliated Hosp 1,Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China
[7] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Resp Dis, Hangzhou, Peoples R China
[8] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Med Oncol, Shanghai, Peoples R China
[9] Eli Lilly & Co, Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Selpercatinib; RET fusion-positive NSCLC; China; ORR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA02.01
引用
收藏
页码：S888 / S889
页数：2
相关论文
共 50 条
  • [41] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Guan, Haijing
    Sheng, Yanan
    Guo, Wanjie
    Han, Sheng
    Shi, Luwen
    ADVANCES IN THERAPY, 2019, 36 (05) : 1114 - 1125
  • [42] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Haijing Guan
    Yanan Sheng
    Wanjie Guo
    Sheng Han
    Luwen Shi
    Advances in Therapy, 2019, 36 : 1114 - 1125
  • [43] Self-reported depression among patients with non-small cell lung cancer
    Shi, Yan
    Gu, Fen
    Hou, Li-li
    Hu, Yin-qing
    THORACIC CANCER, 2015, 6 (03) : 334 - 337
  • [44] Detection and genotype analysis of human papillomavirus in non-small cell lung cancer patients
    Sarchianaki, Emmanouela
    Derdas, Stavros P.
    Ntaoukakis, Markos
    Vakonaki, Elena
    Lagoudaki, Eleni D.
    Lasithiotaki, Ismini
    Sarchianaki, Anna
    Koutsopoulos, Anastasios
    Symvoulakis, Emmanouil K.
    Spandidos, Demetrios A.
    Antoniou, Katerina M.
    Sourvinos, George
    TUMOR BIOLOGY, 2014, 35 (04) : 3203 - 3209
  • [45] The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations
    Duff, Steve
    Bargiacchi, Francesca
    Norregaard, Chelsea
    Brener, Melanie
    Sullivan, Erin
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (02) : 218 - 231
  • [46] Weekly Paclitaxel/Docetaxel Combined with a Platinum in the Treatment of Advanced Non-Small Cell Lung Cancer: a Study on Efficacy, Safety and Pre-medication
    Zhou, Jian-Nong
    Huang, Xin-En
    Ye, Zhuo
    Li, Chao
    Zhang, Qian
    Lin, Yong
    Jiang, Wei
    Sun, Wei-Li
    Shi, Mei-Qi
    Shu, Yong-Qian
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2009, 10 (06) : 1147 - 1150
  • [47] An acquired CCDC6::RET gene fusion as resistance mechanism for Osimertinib in exon 21 EGFR(L858R)-mutated non-small cell lung cancer and its successful management with Osimertinib and Selpercatinib: a case report and review of literature
    Lormans, Maud
    Van Haecke, Peter
    Demedts, Ingel
    JOURNAL OF CHEMOTHERAPY, 2024,
  • [48] Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China”
    Haijing Guan
    Yanan Sheng
    Wanjie Guo
    Sheng Han
    Luwen Shi
    Advances in Therapy, 2020, 37 : 971 - 972
  • [49] Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China"
    Guan, Haijing
    Sheng, Yanan
    Guo, Wanjie
    Han, Sheng
    Shi, Luwen
    ADVANCES IN THERAPY, 2020, 37 (02) : 971 - 972
  • [50] Long-term survival analysis of patients with non-small cell lung cancer complicated with type 2 diabetes mellitus
    Wang, Gaoxiang
    Li, Xuejiao
    Xiong, Ran
    Wu, Hanran
    Xu, Meiqing
    Xie, Mingran
    THORACIC CANCER, 2020, 11 (05) : 1309 - 1318
12345